Skip to content

Non invasive prenatal testing (NIPT) of fetal genetic disorders in maternal blood

Non invasive prenatal testing (NIPT) of fetal genetic disorders in maternal blood - NIPT genetic disorders

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON50448
Enrollment
400
Registered
2014-05-07
Start date
2014-06-19
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

genetic disorders

Interventions

None listed

Sponsors

Medisch Universitair Ziekenhuis Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Pregnant women and their partners (18+) of which: Group 1: the woman is pregnant after PGD for a chromosomal anomaly or monogenic disorder Group 2: the fetus is at risk for a chromosomal anomaly because of an adverse result of regular NIPT testing (Dutch TRIDENT-1 or -2 study) for aneuploidy with or without additional findings. Group 3: the foetus is at high risk of having a de novo disorder on the basis of ultrasonography findings and couple will undergo PND Group 4: the fetus is at high risk of having inherited a dominant or recessive disorder of his/her affected parent(s) and couple ask for conventional PND General: - the pregnant woman and partner are 18 years or older - the pregnant woman has sufficient understanding of Dutch language and is able to give informed consent.

Exclusion criteria

Exclusion criteria: - in the opinion of the treating physician psychological distress is so severe that asking for participation is not safe. - the pregnant woman is treated for a malignancy - patients in group 1 (testing performed with only PCR or OnePGT for monogenic disorders), group 3 and 4 will be excluded from this study if they do not opt for NIPT (with/without additional findings) or PND (with at least a QF PCR of chromosomes 13, 18, 21)

Design outcomes

Primary

MeasureTime frame
- Develop a non-invasive prenatal test for chromosomal and monogenic abnormalities in the pregnant woman's blood. Doest targeted/genome-wide molecular analysis of cell-free DNA or RNA indicate: - the presence or absence of fetal mutation (s) in maternal plasma - the presence of sufficient concentration of fetal DNA / RNA in maternal plasma to enable reliable diagnosis of monogenic disorders. - the presence of aneuploidies, structural abnormalities, and monogenic disorders - when and how the aberrant cells disappear during prenatal development

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)